On June 27, the US Food and Drug Administration (FDA) announced its approval of Afrezza
(insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic …

OLECK ET AL. disease such as asthma or chronic obstructive pulmonary disease.
Hypoglycemia was demonstrated to be the most common side effect, and frequent glucose …

1072 Journal of Diabetes Science and Technology 8 (6) significant. The early onset of action
of Afrezza compared to insulin aspart likely helped control the postprandial rise in glucose …

Abstract Treatment with Afrezza®(insulin human) inhalation powder in individuals with type
1 diabetes (T1D) reduces HbA1c levels similar to rapid-acting insulin analogs, but with …

Purpose The pharmacologic properties of a recently approved inhaled insulin product, its
unique delivery system, and the results of clinical safety and efficacy trials are reviewed …

240 Journal of Diabetes Science and Technology 12 (2) artificial pancreas (AP) system may
improve postprandial and overall metabolic control. 4 Recent research has shown that …

Insulin human inhalation powder is delivered via an inhaler that can be used for up to 15
days from the date of first use. In patients with type 1 diabetes, insulin human inhalation …

FDA approval of inhaled insulin offered the possibility of a new direction in diabetes care.
Nonetheless, within a year of coming to market, the first inhaled insulin product was …

Purpose: The purpose of this article is to educate nurse practitioners about Afrezza. Data
sources: A comprehensive literature search was conducted using MEDLINE for clinical trial …

Background: Insulin initiation in patients with type 2 diabetes is often delayed because of
concerns about injections. Our objective was to compare the effects of AIR® inhaled insulin …